|Table of Contents|

Analysis of the efficacy and safety of icotinib in EGFR mutated elderly non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 01
Page:
52-54
Research Field:
Publishing date:

Info

Title:
Analysis of the efficacy and safety of icotinib in EGFR mutated elderly non-small cell lung cancer
Author(s):
Pei Fei1; Jia Xiaofeng2; Cao Yongliang3
1.Department of Oncology，Beijing Miyun Hospital，Beijing 101500，China；2.Department of Oncology，Hengshui Second Hospital，Hebei Hengshui 053000，China;3.The Inspection Department，Hangzhou Ringpu Gene Technology Co Ltd，Zhejiang Hangzhou 311100，China.
Keywords:
icotinib; EGFR mutant; elderly non-small cell lung cancer; clinical effect; safety
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.01.013
Abstract:
Objective：To investigate the effects and safety of icotinib in EGFR mutant elderly patients with non-small cell lung cancer.Methods：110 elderly patients with EGFR mutated non-small cell lung cancer who were admitted during April 2015 and June 2017 were randomly divided into two groups：Control group(n=55) and observation group(n=55).The control group was given the treatment of gefitinib，the observation group with icotinib treatment.2 groups of serum C reactive protein(CRP)，serum amyloid A(SAA)，interleukin-6(IL-6) and interleukin 2 receptor(IL-2R) level were determined by enzyme-linked immunosorbent assay.Comparison of 2 groups of clinical efficacy and safety.Results：After 4 weeks of treatment，CR+PR rate in the observation group(34.55%) were higher than the control group(24.45%)(P<0.05).There was no statistically significant of pre-inflammatory cytokine levels between the two groups(P>0.05).The 2 groups of CRP，SAA，IL-6 and IL-2R levels were increased after chemotherapy.In observation group,the CRP，SAA，IL-6 and IL-2R level were lower than the control group after 4 weeks of treatment(P<0.05).The adverse reaction incidence rate in observation group(21.82%) was lower than the control group(32.73%)(P<0.05).Conclusion：Icotinib used to treat EGFR mutant elderly patients with non-small cell lung cancer is helpful to improve the clinical curative effect，decrease the level of inflammatory factors，high safety，and is worthy of popularization and application.

References:

[1]Li Xi，Qin Na，Wang Jinghui，et al.Clinical observation on the treatment of advanced non-small cell lung cancer with definite EGFR mutation status by ictinib hydrochloride［J］.Chinese Journal of Lung Cancer，2015，18(12)：734-739.［李曦，秦娜，王敬慧，等.盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察［J］.中国肺癌杂志，2015，18（12）：734-739.］
[2]Chen Hui，Wang Hanping，Zhang Li，et al.The therapeutic value and safety of icotinib as first-line treatment of advanced non-small cell lung cancer patients［J］.Chinese Journal of Internal Medicine，2017，56(1)：39-43.［陈惠，王汉萍，张力，等.盐酸埃克替尼一线治疗晚期非小细胞肺癌的疗效与安全性［J］.中华内科杂志，2017，56（1）：39-43.］
[3]Minuti G，D'Incecco A，Cappuzzo F.Current and emerging options in the management of EGFR mutation-positive non-small-cell lung cancer：Considerations in the elderly［J］.Drugs & Aging，2015，32（11）：907-916.
[4]Jiang Xiaowen，Wang Wenxian，Zhang Yiping.Clinical analysis of patients with advanced non-small cell lung cancer(NSCLC) treated with icotinib［J］.Chinese Journal of Lung Cancer，2016，19(4)：200-206.［蒋小雯，王文娴，张沂平.埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析［J］.中国肺癌杂志，2016，19（4）：200-206.］
[5]Wang Linmei，Liu Jianbo，Shao Runxia，et al.Icotinib on non-small cell lung cancer cell proliferation，apoptosis and its influence mechanism of Shandong［J］.Shandong Medicine，2016，56(38)：9-12.［王林梅，刘剑波，邵润霞，等.盐酸埃克替尼对非小细胞肺癌细胞增殖、凋亡的影响及其机制探讨［J］.山东医药，2016，56（38）：9-12.］
[6] Jiang XW，Bai N，Cao J，et al.Analysis of the efficacy and safety of icotinib in the treatment of non-small cell lung cancer［J］.Chinese Journal of Clinical Pharmacology，2016，32(18)：1714-1716.［江学维，白楠，曹江，等.埃克替尼治疗非小细胞肺癌的有效性及安全性的Meta分析［J］.中国临床药理学杂志，2016，32（18）：1714-1716.］
[7]Inomata M，Shimokawa K，Tokui K，et al.Appetite loss as an adverse effect during treatment with EGFR-TKIs in elderly patients with non-small cell lung cancer［J］.Anticancer Research，2016，36（9）：4951.
[8]Yamada K，Aono H，Hosomi Y，et al.A prospective，multicentre phase Ⅱ trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR，mutations pretreated with chemotherapy：Thoracic oncology research group 0911［J］.European Journal of Cancer，2015，51（14）：1904.
[9] Huang WZ，Zhou F，Pan DC，et al.efficacy and safety of icotinib and standard second-line chemotherapy in the treatment of advanced non-small cell lung cancer［J］.Guangdong Medicine，2016，37(s2)：184-186.［黄万钟，周锋，潘达超，等.埃克替尼与标准二线化疗治疗晚期非小细胞肺癌的效果及安全性［J］.广东医学，2016，37（s2）：184-186.］
[10]Wang Wenxian，Zheng Lei，Song Zhengbo，et al.Therapeutic effect and safety of icotinib in elderly patients with advanced non-small cell lung cancer［J］.Chinese Journal of Geriatrics，2015，34(11)：1247-1249.［王文娴，郑蕾，宋正波，等.埃克替尼治疗老年晚期非小细胞肺癌患者的疗效和安全性［J］.中华老年医学杂志，2015，34（11）：1247-1249.］
[11]Chen Wenjie，Li Gaofeng.Research progress on molecular targeted therapy of non-small cell lung cancer［J］.Modern Oncology，2017，25(12)：1994-1996.［陈文杰，李高峰.非小细胞肺癌的分子靶向治疗研究进展［J］.现代肿瘤医学，2017，25(12)：1994-1996.］
[12] Dai Yuchun，Sun Yue，Zhang Peng.A preliminary analysis of the therapeutic effect and adverse reactions of icotinib in the treatment of 30 cases of non-small cell lung cancer with brain metastasis［J］.Medical Journal of Chinese People's Liberation Army，2016，41(6)：492-495.［戴宇翃，孙越，张鹏.埃克替尼治疗30例非小细胞肺癌脑转移疗效及不良反应的初步分析［J］.解放军医学杂志，2016，41（6）：492-495.］
[13] Xie Zhonghai，Shen Qibin，Li Hongwei，et al.Clinical study of icotinib tablets combined with thoracoscopic minimally invasive treatment of non-small cell lung cancer［J］.Chinese Journal of Clinical Pharmacology，2017，33(13)：1181-1183.［谢忠海，沈琦斌，李鸿伟，等.埃克替尼片联合胸腔镜微创治疗非小细胞肺癌的临床研究［J］.中国临床药理学杂志，2017，33（13）：1181-1183.］
[14] Wang Yun，Jiang Xue，Wang Ying.Clinical efficacy of icotinib hydrochloride in the treatment of 45 cases of advanced non-small cell lung cancer［J］.Journal of Oncology，2016，22(03)：176-179.［王云，蒋雪，王莹.盐酸埃克替尼治疗45例晚期非小细胞肺癌的临床疗效分析［J］.肿瘤学杂志，2016，22(03)：176-179.］
[15]Wang Jibin，Zhou Shuang，Zhou Ying，et al.Comparison of tyrosine kinase inhibitor with chemotherapy in the treatment of advanced non-small cell lung cancer［J］.Chinese Journal of Clinical Pharmacology，2016，32(19)：1793-1796.［王继斌，周双，周颖，等.比较酪氨酸激酶抑制剂与化疗二线治疗晚期非小细胞肺癌的Meta分析［J］.中国临床药理学杂志，2016，32（19）：1793-1796.］
[16]Yuan Dongmei，Song Yong.The accuracy of first-line treatment of advanced non-small cell lung cancer with epidermal growth factor receptor sensitive mutation positive［J］.Chinese Journal of Oncology，2017，39(2)：98-101.［袁冬梅，宋勇.表皮生长因子受体敏感突变阳性晚期非小细胞肺癌内科一线治疗的精准化［J］.中华肿瘤杂志，2017，39（2）：98-101.］
[17] Expert Group on Epidermal Growth Factor Receptor Gene Mutation Detection in Chinese Patients with Non-Small Cell Lung Cancer.Consensus on epidermal growth factor receptor gene mutation detection in chinese patients with non-small cell lung cancer［J］.Chinese Journal of Pathology，2016，45(4)：217-220.［中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组.中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识（2016版）［J］.中华病理学杂志，2016，45（4）：217-220.］

Memo

Memo:
北京市卫生和计划委员会首都卫生发展科研专项项目资助（编号：2018-01-2199）
Last Update: 2018-11-30